Ten international pharmaceutical manufacturers have been
included in the register for companies with a dominant position in
or control over at least 35% of a particular market.
The ten companies are the Russian branches of IHCC, Johnson&
Johnson, Galen Pharma, Roche-Moscow, Novartis Pharma, BIOTECH,
Nycomed Distribution Center, Schering AG, Astellas Pharma and Novo
Nordisk.
Roche, Novartis, Bayer-Schering, Nycomed, Johnson & Johnson
and Novo Nordisk were reported by market research group DSM as
having only 17.8% of the total monetary value of the Russian
pharmaceutical market in 2008.
The Federal Antimonopoly Service has analysed the Russian market
for drugs to treat haemophilia, cystic fibrosis, hypophysial
nanism, Gaucher's disease, myeloleukemia and multiple
sclerosis, and those used after organ or tissue transplants. There
are no Russian analogues for the drugs manufactured by these
companies. It decided that the companies have a dominant position
in this
